Drug Trial Radar · NCT01979900
Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
Last checked: Nov 19, 2026Latest source record: Jun 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,000
Actual
Start
Oct 2013
Primary completion
Nov 26, 2017
Study completion Nov 26, 2017
Sponsor
- Lead sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Guangxi Center for Disease Control and Prevention; Liuzhou Center for Disease Control and Prevention,China; Rongshui County Disease Control and Prevention,China; Liucheng County Disease Control and Prevention,China; Jin Chengjiang Center for Disease Control and Prevention,China; National Institutes for Food and Drug Control, China; Air Force Military Medical University, China; Simoon Record Pharma Information Consulting Co., Ltd.
- First posted
- Nov 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 15 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Mycobacterium Vaccae for Injection (Trade Name "Vaccae") is a kind of bio-products developed by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.,and got "The New Drug Certificate "in 1999. Vaccae has been approved for adjuvant therapy of tuberculosis(TB), and is also the only recommended drug in TB immunotherapy by WHO. It was approved for production and sale by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd. in 2001, and got favourable comment in therapy of tuberculosis. The purpose of this study is to add new indications for Vaccae, mainly to prevent Tuberculosis for high risk groups of Tuberculosis Infection . In December 2012, China Food and Drug Administration approved of the plan "Phase III Clinical Study of Efficacy and Safety of Mycobacterium Vaccae to Prevent Tuberculosis in high risk groups of Tuberculosis Infection". In the test, 10,000 cases whose skin tests of PPD are strongly positive are enrolled. Using random, double-blind, and placebo-controlled methods, the study is carried out to evaluate the efficacy and safety of Vaccae in preventing Tuberculosis. Meanwhile, in this test, TB incidence and degree of pathological changes of experimental group are lower than that of control group, and no drug-related SAEs are reported in treatment groups.
Conditions
- Tuberculosis
Interventions
VaccaeDrug
One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
placeboDrug
One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well,once every 2 weeks, 6 times totally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The whole TB incidence after injection of VaccaeTime frame: Terminal Stage: two years after the last group of subjects enrolled
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Jin Chengjiang Center for Diseases Control and Prevention, Hechi, Guangxi
Hechi, Guangxi, China
Liucheng County Diseases Control and Prevention, Liuzhou, Guangxi
Liuzhou, Guangxi, China
Liuzhou Center for Diseases Control and Prevention, Liuzhou, Guangxi
Liuzhou, Guangxi, China
Rongshui County Diseases Control and Prevention, Liuzhou, Guangxi
Liuzhou, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.